Long-Term Adherence Study of PCSK9 Inhibitors (Inclisiran, Evolocumab, Alirocumab)
Summary
ClinicalTrials.gov registered observational study NCT07543731 on April 22, 2026, evaluating long-term adherence and persistence to three PCSK9 inhibitors—inclisiran, evolocumab, and alirocumab—in real-world clinical practice. The study focuses on patients with familial hypercholesterolemia and atherosclerotic cardiovascular disease. This is an informational registry entry with no compliance obligations imposed.
“This study aims to evaluate the long-term adherence and persistence to inclisiran and anti-proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies (mAbs) in real-world clinical practice.”
About this source
ClinicalTrials.gov is the NIH-run registry of every clinical trial conducted in the United States, plus most international trials sponsored by US-based companies or institutions. By federal law, sponsors must register Phase 2 through Phase 4 studies before enrolling patients and post results within a year of completion. This feed tracks every new trial registration and study update, around 700 a month: drug interventions, device studies, behavioral protocols, observational research. Watch this if you scout drug candidates moving into mid or late-stage development, monitor competitor pipelines, or follow rare disease research where new trials signal patient hope. GovPing parses sponsor, phase, intervention, and target indication on each entry.
What changed
ClinicalTrials.gov registered a new observational study examining real-world long-term adherence and persistence to PCSK9 inhibitors (inclisiran, evolocumab, alirocumab) in patients with cardiovascular disease and familial hypercholesterolemia. The study is categorized as observational with no interventional component. No compliance deadlines, penalties, or regulatory obligations are associated with this registry entry. Pharmaceutical companies and clinical researchers involved in PCSK9 inhibitor development or post-marketing surveillance may monitor study findings for insights into patient adherence patterns.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
A Real-World Study of Long-Term Adherence and Persistence to Inclisiran, Evolocumab, and Alirocumab
Observational NCT07543731 Kind: OBSERVATIONAL Apr 22, 2026
Abstract
This study aims to evaluate the long-term adherence and persistence to inclisiran and anti-proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies (mAbs) in real-world clinical practice.
Conditions: Cardiovascular Diseases, Atherosclerotic Cardiovascular Disease, Hypercholesterolemia, Familial
Mentioned entities
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.